文献速递乳腺癌

在HER2阴性早期乳腺癌女性中,新辅助贝伐珠单抗联合多西他赛后序贯氟尿嘧啶、表柔比星和环磷酰胺的3.5年无病生存和总生存:ARTemis试验

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.
PubMed 文献 · Ann Oncol · 2017-01-01

ARTemis试验将800例HER2阴性早期乳腺癌患者随机分配至多西他赛序贯FEC(D-FEC)±4周期贝伐珠单抗(Bev+D-FEC)。中位随访3.5年,两治疗组无病生存(DFS)和总生存(OS)相似。达到病理完全缓解(pCR)者DFS和OS显著改善,但存在显著异质性,D-FEC达到pCR的改善幅度大于Bev+D-FEC。

要点

  • 中位随访3.5年,加用贝伐珠单抗未改善DFS(HR=1.18,95%CI 0.89-1.57,P=0.25)或OS(HR=1.26,95%CI 0.90-1.76,P=0.19)。
  • 达到pCR者DFS显著改善(HR=0.38,95%CI 0.23-0.63,P<0.001),OS亦显著改善(HR=0.43,95%CI 0.24-0.75,P=0.003)。
  • pCR对DFS的改善存在显著异质性(P=0.02),D-FEC达到pCR的改善大于Bev+D-FEC达到pCR。

核心结论

  • 在标准化疗基础上加用短程新辅助贝伐珠单抗未显示DFS或OS获益。
  • D-FEC达到pCR与DFS和OS改善相关,但Bev+D-FEC达到pCR时未观察到相应改善。
  • 因此目前不推荐贝伐珠单抗用于早期乳腺癌。

研究设计与样本

  • ARTemis试验为随机对照试验,共随机分配800例HER2阴性早期乳腺癌患者。
  • 患者随机接受3周期多西他赛后3周期FEC(D-FEC),±4周期贝伐珠单抗(Bev+D-FEC)。
  • DFS和OS按治疗分组以及按中心病理复核的pCR和残余癌症负荷(RCB)分级进行分析。
  • 中位随访3.5年(IQR 3.2-4.4)。

主要发现

  • DFS和OS在各治疗组间相似:DFS HR=1.18(95%CI 0.89-1.57),P=0.25;OS HR=1.26(95%CI 0.90-1.76),P=0.19。
  • 局部病理报告复核和中心组织病理学复核均证实,达到pCR的患者DFS和OS显著改善:DFS HR=0.38(95%CI 0.23-0.63),P<0.001;OS HR=0.43(95%CI 0.24-0.75),P=0.003。
  • 观察到显著异质性(P=0.02);D-FEC达到pCR较Bev+D-FEC达到pCR获得更大的DFS改善。
  • 随着RCB分级增加,DFS和OS显著更差(趋势P<0.0001),该效应在ER阴性组最为明显。

关键数值与推荐

  • DFS:贝伐珠单抗联合组 vs 单纯化疗组 HR=1.18(95%CI 0.89-1.57),P=0.25。
  • OS:贝伐珠单抗联合组 vs 单纯化疗组 HR=1.26(95%CI 0.90-1.76),P=0.19。
  • pCR vs 非pCR:DFS HR=0.38(95%CI 0.23-0.63),P<0.001;OS HR=0.43(95%CI 0.24-0.75),P=0.003。
  • pCR对DFS改善的异质性检验P=0.02。
  • RCB分级与DFS和OS的趋势检验P<0.0001。

临床怎么用

  • 原文结论指出目前不推荐贝伐珠单抗用于早期乳腺癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC) in HER2 negative breast cancer improved the pathological complete response (pCR) rate. We present disease-free survival (DFS) and overall survival (OS) with central pathology review. PATIENTS AND METHODS: Patients were randomized to 3 cycles of D followed by 3 cycles of FEC (D-FEC), ±4 cycles of Bev (Bev + D-FEC). DFS and OS were analyzed by treatment and by central pathology reviewed pCR and Residual Cancer Burden (RCB) class. RESULTS: A total of 800 patients were randomized [median follow-up 3.5 years (IQR 3.2-4.4)]. DFS and OS were similar across treatment arms [DFS hazard ratio (HR)=1.18 (95% CI 0.89-1.57), P = 0.25; OS HR = 1.26 (95% CI 0.90-1.76), P = 0.19). Both local pathology report review and central histopathology review confirmed a significant improvement in DFS and OS for patients who achieved a pCR [DFS HR = 0.38 (95% CI 0.23-0.63), P < 0.001; OS HR = 0.43 (95% CI 0.24-0.75), P = 0.003]. However, significant heterogeneity was observed (P = 0.02); larger improvements in DFS were obtained with a pCR achieved with D-FEC than a pCR achieved with Bev + D-FEC. As RCB class increased, significantly worse DFS and OS was observed (P for trend <0.0001), which effect was most marked in the ER negative group. CONCLUSIONS: The addition of short course neoadjuvant Bev to standard chemotherapy did not demonstrate a DFS or OS benefit. Achieving a pCR with D-FEC is associated with improved DFS and OS but not when pCR is achieved with Bev + D-FEC. At the present time therefore, Bev is not recommended in early breast cancer. CLINICALTRIALS.GOV NUMBER: NCT01093235.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Earl HM, Hiller L, Dunn JA, et al. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial. Ann Oncol. 2017. PMID: 28459938. doi:10.1093/annonc/mdx173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。